2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.80 (Poster) A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK+ non-small celllung cancer (NSCLC) treated with ALK inhibitors

PP01.80 (Poster) A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK+ non-small celllung cancer (NSCLC) treated with ALK inhibitors

Back to course

Pdf Summary

A retrospective observational study was conducted to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK non-small cell lung cancer (NSCLC) who were treated with ALK inhibitors. Specifically, the study aimed to determine real-world differences in quality of life (QoL) between patients who received brigatinib or other FDA approved ALK inhibitors. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer (EORTC QLQ-LC13) was completed by each patient at various time points throughout the study. <br /><br />The results showed that patients receiving brigatinib reported greater improvements in pain relief after medication scores compared to those on alectinib. Additionally, brigatinib was found to provide similar or better pain relief after medication compared to alectinib between 30 and 360 days from study enrollment. Overall, patients receiving brigatinib saw improvements in 66% of the scores reported from 90 to 360 days from study enrollment.<br /><br />However, there were some limitations to the study. Accurate medication start dates were not collected, which limited the ability to control for the length of time patients had been on the medication. The data collected was also patient-generated and may have included biases from individual perspectives. The use of concomitant medication for pain was not collected as part of the study.<br /><br />In conclusion, this real-world study suggests that brigatinib may be tolerated similarly to alectinib, based on patient-reported outcomes. Future studies should further investigate other aspects of quality of life and expand on the patient-reported outcomes used.

Asset Subtitle

Josh Biber

Keywords

retrospective study

observational study

patient-reported outcomes

metastatic ALK non-small cell lung cancer

ALK inhibitors

quality of life

QoL

brigatinib

alectinib

pain relief